Cerenome Will Launch New Cancer CSF Testing Options
The company is expanding its cerebrospinal fluid diagnostics for solid tumors and hematologic malignancies.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe advanced genetic profiling is essential for improving cancer treatment results?
Cerenome announced that it will launch two new molecular profiling tests on October 12, 2026. These tests identify cancer-related molecular abnormalities in patients through the analysis of cerebrospinal fluid specimens.
Why it matters
This expansion allows clinicians to better identify genetic variants in primary CNS tumors, solid tumors metastatic to the brain, and blood-based cancers. The tests provide a broader look at molecular data compared to previous diagnostic capabilities.
The new profiling tests analyze more than 300 cancer-related genes and 1,600 transcripts using DNA and RNA sequencing. While 11,000 previous CNSide tests have been performed since 2020, these specific tests are not cleared by the FDA.
The players
Cerenome
Cerenome is a diagnostics company that manages test ordering, results delivery, and physician support for its molecular profiling platform.
Genomic Testing Cooperative
Genomic Testing Cooperative is an organization that provides DNA and RNA sequencing and complex bioinformatics analysis services.
The details
The tests identify sequence variants, copy-number alterations, and gene fusions within cell-free DNA. Genomic Testing Cooperative supports the initiative by performing the underlying DNA and RNA sequencing and bioinformatics analysis.
Timeline
2020: CNSide test performance began.
July 2026: Collaboration with Genomic Testing Cooperative announced.
October 6, 2026: Commercial launch announcement occurred.
October 12, 2026: Tests become available for ordering.
Health Landscape
This expansion reflects a broader shift toward liquid biopsy applications for monitoring central nervous system malignancies. It follows the pattern of validating diagnostic platforms through peer-reviewed research before commercial scale-up.
Patients at participating institutions may gain access to more comprehensive genetic profiling for brain and hematologic cancers. Because these tests are not FDA-cleared, physicians and patients should discuss the limitations of molecular diagnostic evidence.
The takeaway
Advanced molecular profiling continues to provide clinicians with deeper insights into complex tumor biology through non-invasive fluid analysis. Patients should consult with their oncologists to determine if these specialized tests are appropriate for their specific diagnostic needs.
What happens next
The tests will be officially available for use by healthcare professionals across the United States beginning on October 12, 2026.
Further reading
Learn more about the latest developments in Cancer research and diagnostics.
More information
For detailed technical specifications, visit the CNSide diagnostics platform information.
Live Poll
Do you believe advanced genetic profiling is essential for improving cancer treatment results?
